About the ADAPT children's eczema study

Eczema can have a serious impact on both the child and their family, with constant itching and disturbed sleep. Some children have such severe eczema that the usual treatments do not help them.

 

Children whose eczema is not controlled by applying creams to the skin may need other medicines. These children may be able to take part in this study.

 

IgE is a molecule produced by the body's immune system in children with allergies. It may be important in contributing to eczema in children. The aim of this study is to use the drug, anti-IgE (Xolair or omalizumab), to neutralise and reduce the levels of IgE in children, and improve their eczema.

 

Our aims are to relieve the symptoms of eczema, and reduce the other treatments that these children need.

 


Eczema is a skin condition that affects up to 1 child in 5 in the UK. In eczema, there is inflammation of the skin. This results in redness, blistering, oozing, crusting, scaling, thickening and sometimes pigmentation.

 

More information about eczema: